Evidence map›Paper›PMID 33616296›Full record

ArticleAnnals of clinical and translational neurology2021

In-depth peripheral CD4

Xiao Huan, Sushan Luo, Huahua Zhong, Xueying Zheng, Jie Song, Lei Zhou, Jun Lu, Ying Wang, Yafang Xu, Jianying Xi and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pro-inflammatory cytokines in myasthenia gravis: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Targeting pathogenic Th17.1 cells via JAK-STAT3 pathway: A novel approach with tofacitinib for refractory myasthenia gravis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. An angel or a devil? Current view on the role of CD8Journal of translational medicine · 2024
    Review
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Xiao HuanDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.ORCID 0000-0002-6122-4804
Sushan LuoDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.ORCID 0000-0002-9033-7568
Huahua ZhongDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.ORCID 0000-0002-7852-3982
Xueying ZhengDepartment of Biostatistics, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
Jie SongDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Lei ZhouDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Jun LuDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Ying WangDepartment of Pharmacy, Huashan Hospital Fudan University, Shanghai, China.
Yafang XuDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Jianying XiDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.
Zhangyu ZouDepartment of Neurology, Institute of Clinical Neurology, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China.
Sheng ChenDepartment of Neurology, Institute of Clinical Neurology, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China.ORCID 0000-0002-7934-015X
Chongbo ZhaoDepartment of Neurology, Huashan Hospital Fudan University, Shanghai, China.ORCID 0000-0001-9481-1418
Fudan University · CNFujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMyasthenia gravis (MG) is an autoimmune disease caused by autoantibodies against neuromuscular junctions. Myasthenic crisis (MC) represents the most severe state of MG with high in-hospital mortality. We aimed to identify immune signatures using in-depth profiling in MC, and to assess the correlations between immune biomarkers with clinical severity longitudinally.

methodsWe studied 181 participants including 57 healthy controls, 96 patients with MG who never experienced crisis and 28 MC patients from December 2018 through June 2020. Follow-up visits occurred prospectively from crisis to 6 months off-mechanical ventilation. The frequencies of 20 CD4

resultsPatients in crisis exhibited a proinflammatory CD4

interpretationVigorous inflammatory CD4

Indexed as

CD4-Positive T-LymphocytesAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedMyasthenia GravisSeverity of Illness Index

Identifiers

PMID33616296
PMCPMC8045923
OpenAlexW3132907062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.